Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Company Overview

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Key Stats

• Today's Range: $1.82 to $1.92
• 50-Day Range: $1.72 to $9.80
• 52-Week Range: $1.33 to $10.24
• Volume: 240,194 shs
• Average Volume: 486,368 shs
• Market Capitalization: $55.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.40
• Consensus Rating: Moderate Buy

Actinium Pharmaceuticals Stock Analysis - MarketRank™

Actinium Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 827th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Actinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.38) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Actinium Pharmaceuticals is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Actinium Pharmaceuticals is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Actinium Pharmaceuticals has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATNM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actinium Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Actinium Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ATNM.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.12

News Sentiment

Actinium Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Actinium Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 17 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

ATNM Stock Analysis - Frequently Asked Questions

How have ATNM shares performed this year?

Actinium Pharmaceuticals' stock was trading at $5.24 on January 1st, 2024. Since then, ATNM shares have decreased by 64.1% and is now trading at $1.88.
View the best growth stocks for 2024 here.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) announced its quarterly earnings data on Monday, August, 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02.

When did Actinium Pharmaceuticals' stock split?

Shares of Actinium Pharmaceuticals reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' top institutional shareholders include Marshall Wace LLP (0.86%), Dimensional Fund Advisors LP (0.38%), Bank of New York Mellon Corp (0.29%) and Squarepoint Ops LLC (0.16%).
View institutional ownership trends.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT) and Abiomed (ABMD).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 9/19/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ATNM
• CUSIP: N/A
• CIK: 1388320
• Web: N/A
• Phone: (646) 677-3870
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.40
• High Stock Price Target: $25.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +503.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,820,000.00
• Net Margins: N/A
• Pretax Margin: -52,620.99%
• Return on Equity: -101.69%
• Return on Assets: -48.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.95
• Quick Ratio: 8.95

Sales & Book Value

• Annual Sales: $81,000.00
• Price / Sales: 694.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 29,783,000
• Free Float: 28,592,000
• Market Cap: $56.29 million
• Optionable: Optionable
• Beta: 0.14